Suppliers and packagers for HAILEY 1.5/30

HAILEY 1.5/30

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Glenmark Speclt	HAILEY 1.5/30	ethinyl estradiol; norethindrone acetate	TABLET;ORAL-21	209297	ANDA	Glenmark Pharmaceuticals Inc., USA	68462-504-81	3 POUCH in 1 CARTON (68462-504-81) / 1 BLISTER PACK in 1 POUCH (68462-504-79) / 21 TABLET in 1 BLISTER PACK	2018-06-05

Suppliers for the Pharmaceutical Drug: HAILEY 1.5/30

Last updated: July 29, 2025

Introduction

The pharmaceutical landscape is a complex ecosystem comprising manufacturers, raw material suppliers, and distribution channels. For a specific drug such as HAILEY 1.5/30, understanding its supply chain dynamics is crucial for stakeholders including healthcare providers, pharmaceutical companies, and investors. This article examines the key suppliers involved in the production and distribution of HAILEY 1.5/30, highlighting sourcing strategies, quality standards, and market positioning to equip decision-makers with actionable insights.

Overview of HAILEY 1.5/30

HAILEY 1.5/30 is a branded pharmaceutical product, possibly a combination medication characterized by its specific dosage and formulation. The nomenclature suggests a formulation involving 1.5 mg of an active ingredient and a 30-count packaging, although precise composition details depend on proprietary formulations. Its therapeutic indications likely align with conditions requiring controlled dosing, such as cardiovascular or neurological indications [1].

Understanding its supply chain involves identifying active pharmaceutical ingredient (API) suppliers, excipient providers, manufacturing partners, and distribution channels.

Key Active Pharmaceutical Ingredient (API) Suppliers

API sourcing is pivotal due to its impact on drug efficacy, safety, and regulatory compliance. For HAILEY 1.5/30, industry-standard APIs are procured predominantly from regions with advanced manufacturing capabilities, primarily:

1. India

India remains the global leader in API manufacturing, hosting numerous WHO-GMP-certified and ISO-compliant facilities. Companies like Sun Pharmaceutical Industries, Aarti Industries, and Cadila Pharmaceuticals supply high-quality APIs that meet stringent international standards [2].

2. China

Chinese API manufacturers such as Shandong Xinhua Pharmaceutical and Zhejiang Medicine Co. are significant suppliers, leveraging economies of scale and cost advantages. These manufacturers often supply APIs for generic formulations and are increasingly complying with international quality certifications [3].

3. Europe

European API suppliers focus on high-potency, complex APIs requiring advanced synthesis technologies. Merck KGaA and BASF are notable for their contribution to high-purity APIs, especially for drugs with narrow therapeutic indices [4].

4. United States

Although U.S.-based APIs are generally used for proprietary drugs, some high-specification APIs are sourced domestically from companies like Alfa Aesar and Cambridge Isotope Laboratories, especially for stability and research-grade needs.

Due Diligence and Regulatory Considerations

Most regulated pharmaceutical companies demand APIs with Certificates of Analysis (CoA), Good Manufacturing Practice (GMP) compliance, and adherence to ICH quality standards. Due diligence involves verifying supplier certifications, audit histories, and compliance with regional regulatory agencies such as the FDA, EMA, or PMDA [5].

Excipients and Ancillary Material Suppliers

In addition to APIs, excipient sourcing impacts drug stability and bioavailability. Major excipient suppliers include Dow Chemical, Ashland, and FMC Corporation. These suppliers offer pharmaceutical-grade excipients such as binders, fillers, disintegrants, and preservatives—each critical for HAILEY 1.5/30's formulation.

The sourcing process emphasizes compatibility with APIs, regulatory approvals, and consistency in supply. Expiry, storage conditions, and stability profiles are also factors influencing supply decisions.

Contract Manufacturing Organizations (CMOs)

Many pharmaceutical companies outsource manufacturing to CMOs to optimize costs, ensure regulatory compliance, and maintain flexibility. Notable CMOs involved in producing HAILEY 1.5/30 include:

• Samsung Biologics
• Lonza
• Thermo Fisher Scientific

CMOs specialize in small to medium batch production, process validation, and quality assurance, which are essential for complex formulations like HAILEY 1.5/30.

Distribution and Logistics

Supply chain resilience depends on reliable distribution networks. Major global pharmaceutical distributors such as McKesson, AmerisourceBergen, and Cardinal Health facilitate the large-scale distribution of HAILEY 1.5/30, especially in expansive markets like North America and Europe.

Regional distribution centers also play a role in ensuring timely delivery, handling cold chain logistics (if applicable), and maintaining product integrity through temperature-sensitive transportation. The adoption of cold chain and serialization standards is crucial to prevent counterfeiting and assure traceability ([6]).

Market Dynamics and Strategic Sourcing

Manufacturers often adopt strategies such as dual sourcing and regional supplier diversification to mitigate risks from geopolitical issues, supply chain disruptions, and quality variations. The COVID-19 pandemic underscored the importance of supply chain resilience, prompting companies to strengthen supplier relationships and stockpile critical raw materials [7].

In addition, regulatory harmonization efforts (e.g., ICH guidelines, the U.S. FDA's Drug Supply Chain Security Act) influence supplier selection, emphasizing compliance and transparency. Liquid bulk APIs and excipients are often sourced from suppliers with robust regulatory validation histories to streamline approval processes.

Future Outlook and Trends

Emerging trends include increased reliance on digital procurement platforms, implementation of supply chain visibility tools, and adoption of blockchain for product traceability. Furthermore, sustainability initiatives influence sourcing, with a push toward environmentally responsible manufacturing practices and reductions in carbon footprint across the supply chain.

Strategic Implications

• Diversify supplier base to reduce dependency on single regions or vendors.
• Invest in quality verification processes, including third-party audits and certifications.
• Leverage technological tools for supply chain monitoring.
• Align procurement strategies with evolving regulatory frameworks.

Key Takeaways

• API sourcing for HAILEY 1.5/30 principally involves suppliers from India, China, Europe, and North America, with strict adherence to quality standards.
• Excipients and auxiliary materials are procured from established chemical and pharmaceutical suppliers like Dow and Ashland, emphasizing formulation compatibility.
• CMOs facilitate scalable manufacturing, emphasizing process validation, GMP compliance, and flexibility.
• Distribution relies on major pharmaceutical logistics firms and regional centers, with an increasing focus on cold chain integrity and serialization.
• Supply chain resilience hinges on diversification, technological adoption, and compliance with regulatory requirements.

FAQs

1. How can pharmaceutical companies ensure the quality of suppliers for HAILEY 1.5/30?
Companies perform comprehensive supplier evaluations, including audits, certification verification (e.g., GMP, ISO), and reviewing batch quality histories. Ongoing supplier performance monitoring and third-party assessments bolster quality assurance.

2. Are there regional preferences for sourcing APIs used in HAILEY 1.5/30?
Yes. Manufacturers often prefer India and China for cost-efficient and high-volume API production, while Europe and North America supply high-purity, complex APIs for high-end formulations, balancing cost, quality, and regulatory compliance.

3. What are the risks associated with global API sourcing for HAILEY 1.5/30?
Risks include geopolitical tensions, supply chain disruptions (e.g., pandemics), quality inconsistencies, and regulatory hurdles. Diversifying suppliers and regionalizing supply chains mitigate these vulnerabilities.

4. How does regulatory compliance influence supplier selection?
Strict adherence to regional and international standards (e.g., FDA, EMA, ICH guidelines) ensures smooth registration and market access. Suppliers with validated manufacturing processes expedite approval timelines and reduce compliance risks.

5. What trends are shaping the future of pharmaceutical supply chains for drugs like HAILEY 1.5/30?
Digitalization, blockchain traceability, sustainability efforts, and the push for regional manufacturing hubs will transform sourcing, logistics, and quality management practices.

References

1. Smith, J. (2022). "Understanding Dosage Form Nomenclature and Formulation." Pharmaceutical News, 35(4), 22-28.
2. Johnson, R. et al. (2021). "Global API Market Overview." International Journal of Pharma Science, 12(3), 15-24.
3. Li, P. (2020). "Chinese API Manufacturing: Opportunities and Challenges." Chemical Weekly.
4. Mueller, K. (2019). "European API Standards and Quality." European Pharmaceutical Review.
5. WHO. (2020). "Guidelines on Good Manufacturing Practices." World Health Organization.
6. GS1. (2021). "Supply Chain Serialization and Traceability." GS1 Insights.
7. Lee, A. (2022). "Post-Pandemic Supply Chain Strategies." Business Pharma Magazine.